口服LPCN 1148改善肝硬化男性患者的肌少症和肝性脑病:一项随机、安慰剂对照的2期试验
这项多中心、双盲、2期试验将等待肝移植的肌少症肝硬化男性按1:1随机分配接受口服雄激素受体激动剂LPCN 1148或安慰剂治疗24周。主要终点为L3区域CT测量的骨骼肌指数从基线至24周的变化,LPCN 1148组较安慰剂组平均组间差异为4.4 cm²/m²(95%CI 1.3-7.4,P=0.007);LPCN 1148组显性肝性脑病发作次数更少(P=0.02)。结论认为LPCN 1148改善了肌少症并减少了显性肝性脑病发作次数。
要点
- LPCN 1148组L3骨骼肌指数较安慰剂组平均增加4.4 cm²/m²(95%CI 1.3-7.4,P=0.007)。
- LPCN 1148组显性肝性脑病(CTCAE≥2级)发作次数少于安慰剂组(P=0.02)。
- 两组治疗中出现的不良事件数量和严重程度相似。
核心结论
- LPCN 1148治疗改善了等待肝移植的肌少症肝硬化男性的肌少症,并减少了显性肝性脑病发作次数。
- 这些发现支持对LPCN 1148治疗肌少症和预防肝性脑病复发的疗效开展进一步研究。
研究设计与样本
- 多中心、双盲、2期试验(NCT04874350),将等待肝移植的肌少症肝硬化男性按1:1随机分配接受口服雄激素受体激动剂LPCN 1148或安慰剂治疗24周。
- 共29例参与者(平均年龄59岁,MELD 17)接受至少1剂LPCN 1148(n=15)或安慰剂(n=14)。
- 主要终点为L3区域CT测量的骨骼肌指数从基线至24周的变化,采用预设的改良意向治疗人群分析。
- 次要终点为显性肝性脑病事件数。
主要发现
- 主要终点分析显示,LPCN 1148组(n=15)较安慰剂组(n=10)L3区域CT测量的骨骼肌指数增加,平均组间差异为4.4 cm²/m²(95%CI 1.3-7.4 cm²/m²,P=0.007)。
- LPCN 1148组显性肝性脑病(常见不良事件术语标准≥2级)发作次数少于安慰剂组(P=0.02)。
- 两组治疗中出现的不良事件数量和严重程度相似。
- 两组基线特征相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Sarcopenia is highly prevalent in patients with liver cirrhosis and is associated with adverse clinical outcomes, including HE. Androgen receptor agonists, androgen receptor agonists, can address these conditions through multimodal mechanisms of action; however, their safety and efficacy in patients with cirrhosis have not been well established. APPROACH AND RESULTS: In this multicenter, double-blind, phase 2 trial, men with sarcopenia and cirrhosis awaiting liver transplant were randomized 1:1 to receive either oral Androgen Receptor Agonist LPCN 1148 or placebo for 24 weeks (NCT04874350). The primary end point was the change from baseline to 24 weeks in skeletal muscle index measured by a CT scan of the L3 region, analyzed with a prespecified modified intent-to-treat population. The secondary end point was the number of overt HE events. Twenty-nine participants (mean age=59 y, MELD=17) received at least 1 dose of LPCN 1148 (n=15) or placebo (n=14). Baseline characteristics were similar between groups. Primary end point analysis demonstrated an increase in L3-skeletal muscle index measured by a CT scan of the L3 region in the LPCN 1148 group (n=15) compared to placebo (n=10), with a mean group difference of 4.4 cm 2 /m 2 (95% CI: 1.3-7.4 cm 2 /m 2 , p =0.007). Participants in LPCN 1148 experienced fewer episodes of overt HE (Common Terminology Criteria for Adverse Events grade ≥2; p =0.02) than placebo. The number and severity of treatment-emergent adverse events were similar between arms. CONCLUSIONS: LPCN 1148 treatment improved sarcopenia and reduced the number of overt HE episodes in men with cirrhosis and sarcopenia awaiting liver transplant. These findings support additional research on the efficacy of LPCN 1148 in treating sarcopenia and preventing HE recurrence.
引用
- Bruno BJ, Weavil JC, Ogle J, et al. Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosis: A randomized, placebo-controlled phase 2 trial. Hepatology. 2025. PMID: 39513970. doi:10.1097/HEP.0000000000001146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。